Phase II study of weekly paclitaxel and trastuzumab in anthracycline- and taxane-pretreated patients with HER2-overexpressing metastatic breast cancer

Synergism between anti-HER2 monoclonal antibody (trastuzumab) and paclitaxel has been shown in vitro and in vivo. In previous experiences, weekly administration of trastuzumab and paclitaxel has shown significant activity in metastatic breast cancer. In this phase II study, we evaluated the activity...

Descripción completa

Detalles Bibliográficos
Autores principales: Gori, S, Colozza, M, Mosconi, A M, Franceschi, E, Basurto, C, Cherubini, R, Sidoni, A, Rulli, A, Bisacci, C, Angelis, V De, Crinò, L, Tonato, M
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2004
Materias:
Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2395328/
https://www.ncbi.nlm.nih.gov/pubmed/14710203
http://dx.doi.org/10.1038/sj.bjc.6601485

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2395328/
https://www.ncbi.nlm.nih.gov/pubmed/14710203
http://dx.doi.org/10.1038/sj.bjc.6601485

Ejemplares similares